Delivery Order SPE2DB24D1205-SPE2DB25FCZKT
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Tezspire is a specialty biologic medication used in the treatment of severe asthma, representing the type of high-value...
- The Defense Logistics Agency awarded a $35,153.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. The contract, which is non-set-aside and competitively awarded, carries an ultimate completion date of September 3, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen injectors on August 8, 2025, with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract was issued under a competitive procurement process and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Tezspire is a biologic medication used in the treatment of moderate-to-severe asthma, representing the type of...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion deadline of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $14,061.54 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement executed on July 30, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tezspire is a biologic therapeutic used in the treatment of severe asthma, reflecting DLA's...
- The Defense Logistics Agency awarded a $7,030.77 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 ml pens. The contract, which carries a firm fixed price structure with no set-aside designation, is scheduled for completion by August 12, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, with completion targeted for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for TEZSPIRE 210 mg/1.91 mL pen injections on August 5, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 26, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a small-value transaction...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Tezspire 210 mg/1.91 ml pen auto-injectors. This firm fixed-price delivery order, valued at $4,687.18, carries an ultimate completion date of August 21, 2025, and represents a non-competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZKTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injections, valued at $4,687.18 with a firm fixed price structure. The award was made on August 11, 2025, with an ultimate completion date of September 2, 2025. This delivery order represents a non-set-aside, competitively awarded contract supporting federal pharmaceutical procurement needs. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 billion through December 2026. As a premier pharmaceutical distributor, AmerisourceBergen supplies a comprehensive range of medications and medical commodities to support military and federal healthcare systems. Tezspire is a specialty medication used in the treatment of moderate-to-severe asthma, reflecting the company's role in providing specialized therapeutic agents to support Defense Health Agency operations and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 8/11/25 |